{
    "ticker": "ALLK",
    "name": "Allakos Inc.",
    "description": "Allakos Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of therapeutic antibodies for the treatment of allergic and autoimmune diseases. Founded in 2012 and headquartered in San Carlos, California, Allakos focuses on innovative solutions that target the root causes of these conditions, rather than merely alleviating symptoms. The company's lead product candidate, AK003, is an investigational monoclonal antibody designed to treat eosinophil and mast cell-driven diseases, with a primary focus on conditions such as eosinophilic gastritis and eosinophilic esophagitis. Allakos is committed to advancing its pipeline through rigorous clinical trials, demonstrating its commitment to creating life-changing therapies for patients suffering from severe allergic reactions and related disorders. The company's approach leverages its proprietary technology platform to identify and develop novel therapeutic candidates that have the potential to significantly improve the quality of life for patients. With a strong scientific foundation and a passion for innovation, Allakos aims to revolutionize the treatment landscape for allergic and autoimmune diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Carlos, California, USA",
    "founded": "2012",
    "website": "https://www.allakos.com",
    "ceo": "Robert Alexander",
    "social_media": {
        "twitter": "https://twitter.com/AllakosInc",
        "linkedin": "https://www.linkedin.com/company/allakos/"
    },
    "investor_relations": "https://investors.allakos.com",
    "key_executives": [
        {
            "name": "Robert Alexander",
            "position": "CEO"
        },
        {
            "name": "Marc A. C. G. O. de Jong",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Monoclonal Antibodies",
            "products": [
                "AK003"
            ]
        }
    ],
    "seo": {
        "meta_title": "Allakos Inc. | Innovative Therapeutics for Allergic Diseases",
        "meta_description": "Allakos Inc. is a biotechnology company focused on developing novel therapeutic antibodies for allergic and autoimmune diseases. Learn more about our mission and product pipeline.",
        "keywords": [
            "Allakos",
            "Biotechnology",
            "Therapeutic Antibodies",
            "Allergic Diseases",
            "Eosinophilic Diseases"
        ]
    },
    "faq": [
        {
            "question": "What does Allakos specialize in?",
            "answer": "Allakos specializes in developing therapeutic antibodies for the treatment of allergic and autoimmune diseases."
        },
        {
            "question": "What is the lead product candidate of Allakos?",
            "answer": "The lead product candidate of Allakos is AK003, which targets eosinophil and mast cell-driven diseases."
        },
        {
            "question": "Where is Allakos headquartered?",
            "answer": "Allakos is headquartered in San Carlos, California, USA."
        },
        {
            "question": "When was Allakos founded?",
            "answer": "Allakos was founded in 2012."
        },
        {
            "question": "Who is the CEO of Allakos?",
            "answer": "Robert Alexander is the CEO of Allakos Inc."
        }
    ],
    "competitors": [
        "REGN",
        "VRTX",
        "VRTX",
        "AMGN"
    ],
    "related_stocks": [
        "GILD",
        "BMY",
        "JNJ",
        "MRNA"
    ]
}